Loading…
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2M | $-284M | $-259M | $-214M | -49.1% | -78.0% | 63.9% |
| 2024 | $7M | $-192M | $-158M | $-160M | -21.1% | 2.0% | 11.6% |
| 2023 | $7M | $-139M | $-141M | $-109M | -33.0% | 192.0% | 25.9% |
| 2022 | $2M | $-104M | $-112M | $-106M | -34.4% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 2.36 | 6.88 | 7.02 | 1.54 |
| Operating Revenue | - | 2.36 | 6.88 | 7.02 | 1.54 |
| Operating Expense | - | 109.45 | 148.93 | 202.10 | 288.91 |
| Research And Development | - | 82.26 | 118.01 | 163.55 | 245.07 |
| Selling General And Administration | - | 27.20 | 30.91 | 38.55 | 43.84 |
| Total Expenses | - | 109.45 | 148.93 | 202.10 | 288.91 |
| Operating Income | - | -107.10 | -142.04 | -195.08 | -287.37 |
| Total Operating Income As Reported | - | -115.23 | -154.54 | -195.08 | -287.37 |
| EBITDA | - | -104.20 | -139.03 | -191.90 | -283.99 |
| Normalized EBITDA | - | -98.97 | -139.65 | -229.12 | -312.60 |
| EBIT | - | -107.10 | -142.04 | -195.08 | -287.37 |
| Other Income Expense | - | -5.23 | 0.61 | 37.22 | 28.61 |
| Pretax Income | - | -112.32 | -141.43 | -157.86 | -258.76 |
| Tax Provision | -0.23 | 0 | 0 | - | - |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -112.32 | -141.43 | -157.86 | -258.76 |
| Net Income From Continuing And Discontinued Operation | - | -112.32 | -141.43 | -157.86 | -258.76 |
| Net Income From Continuing Operation Net Minority Interest | - | -112.32 | -141.43 | -157.86 | -258.76 |
| Net Income | - | -112.32 | -141.43 | -157.86 | -258.76 |
| Net Income Common Stockholders | - | -112.32 | -141.43 | -157.86 | -258.76 |
| Net Income Including Noncontrolling Interests | - | -112.32 | -141.43 | -157.86 | -258.76 |
| Normalized Income | - | -107.10 | -142.04 | -195.08 | -287.37 |
| Diluted NI Availto Com Stockholders | - | -112.32 | -141.43 | -157.86 | -258.76 |
| Basic Average Shares | - | 46.89 | 48.45 | 64.40 | 66.42 |
| Diluted Average Shares | - | 46.89 | 48.45 | 64.40 | 66.42 |
| Reconciled Depreciation | - | 2.90 | 3.01 | 3.18 | 3.38 |
| Total Unusual Items | - | -5.23 | 0.61 | 37.22 | 28.61 |
| Total Unusual Items Excluding Goodwill | - | -5.23 | 0.61 | 37.22 | 28.61 |
| Special Income Charges | - | -8.14 | -12.50 | 0 | 0 |
| Other Special Charges | - | 15 | 12.50 | - | - |
| Write Off | 0 | - | - | - | - |
| Impairment Of Capital Assets | 3.50 | 0 | 0 | - | - |
| Restructuring And Mergern Acquisition | -1.40 | -6.86 | 0 | 0 | - |
| Gain On Sale Of Security | - | 2.91 | 13.11 | 37.22 | 28.61 |
| General And Administrative Expense | - | 27.20 | 30.91 | 38.55 | 43.84 |
| Other Gand A | - | 27.20 | 30.91 | 38.55 | 43.84 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Celldex Therapeutics, Inc.this co. | CLDX | $2.3B | -9.08 | 4.46 | -49.1% | -8.18 |
| Heartflow, Inc. | HTFL | $2.5B | -21.27 | 8.26 | -38.8% | -26.44 |
| Vera Therapeutics, Inc. | VERA | $2.4B | -8.00 | 3.96 | -49.6% | -7.27 |
| Axogen, Inc. | AXGN | $2.3B | - | 17.49 | -12.2% | 4471.19 |
| Immunome, Inc. | IMNM | $2.2B | -10.49 |
| - |
| - |
| - |
| - |
| - |
| - |
| 3.51 |
| -33.5% |
| -7.14 |
| Mineralys Therapeutics, Inc. | MLYS | $2.2B | -14.28 | 3.41 | -23.9% | - |
| Enliven Therapeutics, Inc. | ELVN | $2.2B | -20.85 | 4.70 | -22.6% | -17.28 |
| BioCryst Pharmaceuticals, Inc. | BCRX | $2.2B | 8.16 | -18.07 | -221.4% | 7.20 |
| Kodiak Sciences Inc. | KOD | $2.1B | - | 13.58 | -146.1% | - |
| Peer Median | - | -12.39 | 4.33 | -36.2% | -7.20 | |